REMS
Contraindicated in:
Use Cautiously in:
Chronic hepatitis B virus (HBV) infection (may exacerbate following discontinuation)
;Exercise Extreme Caution in:
Derm: alopecia, erythema multiforme, rash, urticaria
Endo: hyperglycemia
F and E: lactic acidosis
GI: anorexia, diarrhea, nausea, vomiting, ↑liver enzymes, abdominal discomfort, dyspepsia, HEPATOMEGALY WITH STEATOSIS, PANCREATITIS ( IN PEDIATRIC PATIENTS)↑ in pediatric patients)
Hemat: anemia, neutropenia, pure red cell aplasia
MS: musculoskeletal pain, arthralgia, muscle weakness, myalgia, rhabdomyolysis
Neuro: fatigue, headache, insomnia, malaise, neuropathy, depression, dizziness, SEIZURES
Resp: cough
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), immune reconstitution syndrome
Drug-drug:
HIV-1 Infection
Renal Impairment
Chronic Hepatitis B
Renal Impairment
Therapeutic Classification: antiretrovirals, antivirals
Pharmacologic Classification: nucleoside reverse transcriptase inhibitors
Absorption: Well absorbed after oral administration (86% in adults, 66% in infants and children).
Distribution: Distributes into the extravascular space. Some penetration into CSF; remainder of distribution unknown.
Half-Life: 57 hr.
(plasma concentrations)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | unknown | 0.9 hr‡ | 12 hr |
‡On an empty stomach; peak levels occur at 3.2 hr if lamivudine is taken with food. Food does not affect total amount of drug absorbed.
Do not stop taking without consulting health care provider. Discontinuing therapy may lead to severe exacerbations. Inform patient of importance of HBV testing before starting antiretroviral therapy.
NDC Code